GNLB - Sector: Healthcare ---Industry: Biotechnology & Drugs

[gambler2075]

good info on the trial
from a bioethics journal, but whatever...

http://www.bioethics.net/journal/j_articles.php?aid=713

"The Phase II/III trials of the vaccine, with RNA soldiers as subjects, were completed in late 2003, but the results have yet to be made public. "

This is what is being made public on Dec 12.

[newnewbie]

The main reason why the Phase II results have not been released yet is because the vaccine has been undergoing long-term immunogenicity testing to ensure  that the large investment required for a manufacturing establishment is warranted.

Now, GSK announced several months ago that it is building a plant to manufacture vaccines. Did noy say what vaccines, but given the region where the plant is being (or will be built), I would suspect is for Hep E.

Do your own DD

[gambler2075]

I give this a 95% chance that we get a positive pr about hep E vaccine tomorrow, premarket.

which is why I am long 40k shares after I left nabi.
http://www.3stocksonfire.org/trading/index.php?topic=3855.0

We'll see if I have egg on my face tomorrow

gambler

[setravis]

GNLB is not an OTCBB or Pink Sheet listed.
This pick is located on the Stock Picking Board....here..

http://www.3stocksonfire.org/trading/index.php?topic=355.0

[setravis]

IMHO, still looks like it is trying to form a Rounding Bottom (Reversal) Pattern.

BRIEF: For the nine months ended 30 September 2005, Genelabs Technologies, Inc.'s revenues totaled $5.1M, up from $1.8M. Net loss from continuing operations fell 40% to $8.6M. Revenues reflect higher contract revenue from research collabration and license agreement with Gilead Sciences. Net income was offset by lower research & development expense, decreased general & administrative expense and higher interest income, net. http://www.genelabs.com

Technicals
Close Above the 50-day EMA

Last Price Quote is:
5.70%above 13-day EMA
0.98%above 50-day EMA
RS Rating: 16 

Fundamentals
Key Data:
Market Cap (M): $41.77 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: Hold

[setravis]

Overlooked this news of Reverse Split.......
************************************************
• Genelabs Announces Board Approval of Reverse Stock Split
PR Newswire (Tue, Dec 6) 

Press Release Source: Genelabs Technologies, Inc.


Genelabs Announces Board Approval of Reverse Stock Split
Tuesday December 6, 6:30 pm ET


REDWOOD CITY, Calif., Dec. 6 /PRNewswire-FirstCall/ -- Genelabs Technologies, Inc. (Nasdaq: GNLB - News) announced today that its board of directors has approved the implementation of a one-for-five reverse split of the company's common stock. The reverse split was previously approved by the company's shareholders at the company's annual shareholder meeting on June 14, 2005.


Genelabs' common stock will begin trading on a split-adjusted basis when the market opens on Monday, December 19, 2005. For a period of 20 trading days beginning December 19, 2005, Genelabs' common stock will trade on a post-split basis under the trading symbol "GNLBD" as an interim symbol to denote its new status. After this 20 trading day period, Genelabs' common stock will resume trading under the symbol "GNLB."

The reverse split is intended to broaden Genelabs' investor base and help the company regain compliance with Nasdaq's $1.00 minimum bid price listing requirement by increasing the share price and decreasing the number of shares, warrants and options outstanding.

Genelabs had 88,868,865 shares of common stock issued and outstanding at the end of trading on December 5, 2005, the date of board approval of the reverse split. When the market opens on December 19, 2005, there should be approximately 17,773,773 shares issued and outstanding if no warrants or options are exercised in the interim.

Genelabs will not issue fractional shares of common stock following the reverse split. Shareholders otherwise entitled to fractional shares will receive a cash payment equal to the average closing price of Genelabs common stock for the 30 trading days ending five days preceding the effective date of the reverse split. Additional information about the reverse stock split is available in Genelabs' definitive proxy statement filed with the Securities and Exchange Commission on April 29, 2005.

About Genelabs

Genelabs Technologies, Inc. is a biopharmaceutical company focused on the discovery and development of pharmaceutical products to improve human health. We have built drug discovery capabilities that can support various research and development projects. Genelabs is currently concentrating these capabilities on discovering novel compounds that selectively inhibit replication of the hepatitis C virus and advancing preclinical development of compounds from this hepatitis C virus drug discovery program, while also developing a late-stage product for lupus. We believe that these high-risk, potentially high reward programs focus our research and development expertise in areas where we have the opportunity to generate either first-in-class or best-in-class products that will address diseases for which current therapies are inadequate. For more information, please visit www.genelabs.com.

NOTE: Genelabs® and the Genelabs logo are registered trademarks and Prestara(TM) is a trademark of Genelabs Technologies, Inc.

NOTE ON FORWARD LOOKING STATEMENTS AND RISKS: This press release contains forward-looking statements including statements regarding the timing of the effectiveness of the reverse split of Genelabs' common stock and the trading price of Genelabs common stock after the reverse split is implemented. These forward-looking statements are based on Genelabs' current expectations and are subject to uncertainties and risks that could cause actual results to differ materially from the statements made. Uncertainties and risks include, without limitation, fluctuations in Genelabs' stock price; events which reduce Genelabs' future prospects, problems in initiating manufacturing or IND-enabling studies; failures or setbacks in our HCV research programs or in our collaboration with Gilead; progress and announcements by competitors regarding their HCV programs; regulatory problems or delays regarding Prestara(TM), including an adverse response from the FDA or a determination to discontinue development of Prestara; increases in expenses and Genelabs' capital requirements and history of operating losses. Please see the information appearing in Genelabs' filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, under the captions "Risk Factors" and "Forward-Looking Statements" for more discussion regarding these uncertainties and risks and others associated with the company's research programs, early stage of development and other risks which may affect the company or cause actual results to differ from those included in the forward-looking statements. Genelabs does not undertake any obligation to update these forward-looking statements or risks to reflect events or circumstances after the date of this release.


     Contact:
     Matthew M. Loar
     Chief Financial Officer
     Phone: 650-562-1424




--------------------------------------------------------------------------------
Source: Genelabs Technologies, Inc.

[setravis]

Possible double bottom play in.

Up in the after hours...
GENELABS TECH INC (NasdaqSC:GNLB) Delayed quote data 

After Hours (RT-ECN): 2.30  0.10 (4.55%) 

Company reported higher revenue/hep C virus drug, in collaboration with Gilead Sciences.
Revenue $1.7M vs. .4M same qtr year ago.

Technicals
Close Above the 50-day EMA
Percentage Gainer

Last Price Quote is:
14.44%above 13-day EMA
7.49%above 50-day EMA
RS Rating: 9 

Fundamentals
Key Data:
Market Cap (M): $35.01 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: Hold

[jpm]

Up today 110% 

next stop $2.50 tomorrow......

yessssssss

I Love this game

[AussieTrader]

Up today 110% 

next stop $2.50 tomorrow......

yessssssss

I Love this game

So do you have GNLB? I haven't seen you post on it before?

[brucey]

 
GNLB----Huge volume with good news
from 0.76-2.45,222.3% up....

[setravis]

 

Volume: 24,137,126
Avg Vol (3m): 85,346.2


Technicals
Most Actives
Gap Up
Percentage Gainer

Last Price Quote is:
185.84%above 13-day EMA
110.45%above 50-day EMA
RS Rating: 93 

Fundamentals
Key Data:
Market Cap (M): $13.72 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: Hold

[setravis]

bizjournals.com
Genelabs inks hepatitis deal with Novartis
Monday June 5, 12:35 pm ET


Genelabs Technologies Inc. inked a research and sales deal with drug giant Novartis, which will develop and sell products using Genelabs' hepatitis C research program.
Redwood City-based Genelabs (NASDAQ: GNLB - News) will get about $20 million over two years, including an up front payment of $12.5 million. It also stands to get royalties on sales of any successful products from the deal.
 
James Smith, president and CEO of Genelabs, said drug candidates found using his company's technology may complement other hepatitis C drugs being developed by Novartis (NYSE: NVS - News), which is based in Basle, Switzerland.

Hepatitis C is a virus that attacks the liver. No existing vaccine can protect against infection by the virus.

Genelabs has about 66 employees. Novartis has 90,000.

Published June 5, 2006 by San Francisco Business Times

[jpm]

news on CNBC...


Novartis will pay $5 dollars a share for Genelabs Technologies (GNLB)...

[la-onda]

not published on the websites from Novartis, Genelabs Technologies & CNBC  !!!
latest news from Monday:
http://biz.yahoo.com/bizj/060605/1297795.html?.v=1

[setravis]

Motley Fool
Novartis Can't Say No
Wednesday June 7, 12:14 pm ET
By Stephen D. Simpson, CFA


I'm beginning to wonder whether there are any deals that Novartis (NYSE: NVS - News) hasn't accepted in the past few quarters. In the last few days, the company has sealed three separate deals to add compounds to its pipeline -- at the cost of hard cash.


Today, news broke that Novartis will be buying British biotech company NeuTech Pharma for about $569 million in cash. For that price, Novartis is getting a company focused on treatment-resistant infections, with two late-stage drugs in the pipeline. Mycograb, targeted at dangerous fungal infections, could be submitted for U.S. approval in 2009, while Aurograb (for staph infections) looks like it's about a year later in the queue.

But wait, there's more!

Yesterday, the company announced a deal with Human Genome Sciences (Nasdaq: HGSI - News) for the rights to Albuferon, a hepatitis C treatment. Assuming this drug reaches approval (a phase 3 trial should begin later this year), the companies would cooperate in the U.S. market, while Novartis would handle foreign sales and distribution. Under this deal, Novartis pays $45 million up front and potentially more than $500 million in future milestones.

But wait, there's even more!

Novartis also announced a licensing deal with Genelabs Technologies (Nasdaq: GNLB - News). The deal will cost Novartis about $20 million over two years, and as much as $175 million in potential milestones, if a successful drug comes out of this agreement. The disease in question? Yep, you guessed it -- hepatitis C.

Obviously, Novartis wants to establish a major franchise in hepatitis C, given both of these deals and past agreements with Idenix (Nasdaq: IDIX - News) and Anadys (Nasdaq: ANDS - News). There's certainly a ripe and underserved market here, and I also think that Novartis has a logical underlying philosophy. It's looking at several different and possibly complementary approaches to the disease, with the hope of combining them in different ways to treat various subtypes of the disease and patients who don't adequately respond to existing therapies.

If you're a company with a hep-C drug or a development program in that area, stay by the phone -- Novartis will probably be calling you, too. As for Novartis shareholders, I'm not quite sure what to think. I know it takes money to build a pipeline, but these guys have been doing deals left and right. Then again, we're talking about a strong pharmaceutical company in a weak sector that's still somewhat undervalued -- not exactly the worst story I've seen this week.

Fool contributor Stephen Simpson but has no financial interest in any stocks mentioned (that means he's neither long nor short the shares).